Bio-Rad Laboratories reported $2.94B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Agilent USD 4.76B 148M Mar/2026
Becton, Dickinson and Co. USD 8.01B 1.18B Mar/2026
Bio Techne USD 688.05M 50.62M Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Bruker USD 2.1B 108.9M Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Danaher USD 13.38B 554M Jun/2026
General Electric Aerospace USD 39.7B 664M Jun/2026
Illumina USD 2.83B 96M Jun/2026
IQVIA Holdings USD 6.23B 6M Jun/2026
Laboratory Of America USD 3.81B 743.9M Jun/2026
Merck USD 35.02B 8.5B Mar/2026
Mettler Toledo International USD 1.35B 15.48M Jun/2026
Myriad Genetics USD 289M 23.8M Jun/2026
OraSure Technologies USD 240.78M 21.13M Mar/2026
Pacific Biosciences Of California USD 369.52M 5.54M Mar/2026
Quest Diagnostics USD 2.84B 278M Jun/2026
Repligen USD 1.2B 39.19M Jun/2026
Revvity USD 2.13B 111.43M Mar/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Siemens EUR 68.95B 1.04B Mar/2026
Standard Biotools USD 521.45M 67.19M Mar/2026
Thermo Fisher Scientific USD 23.36B 1.05B Jun/2026
Tosoh JPY 798.07B 38.8B Mar/2026
Waters USD 3.72B 1.73B Mar/2026